irinotecan has been researched along with Lymphoma, B-Cell in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Bhattacharyya, J; Hoshi, M; Kimura, A; Mihara, K; Ohtsubo, M; Sakai, A; Takei, Y; Takihara, Y; Yanagihara, K; Yasunaga, S | 1 |
| Fukushima, T; Hirose, Y; Karasawa, H; Kawabata, H; Kawanami, T; Masaki, Y; Ogawa, N; Sawaki, T; Shimoyama, K; Sugai, S; Umehara, H; Wano, Y | 1 |
| Bessho, M; Higashihara, M; Kohuri, M; Niitsu, N | 1 |
| Amaya, N; Tsutani, H; Ueda, T; Yamauchi, T; Yoshida, A; Yoshio, N | 1 |
| Inai, K; Kishi, S; Morinaga, K; Naiki, H; Tsutani, H; Ueda, T | 1 |
| Kumagai, K; Sakai, C; Saotome, T; Takagi, T; Tamaru, J | 1 |
| Asai, J; Fujimoto, T; Miyo, T; Nagashima, G; Suzuki, R | 1 |
2 trial(s) available for irinotecan and Lymphoma, B-Cell
| Article | Year |
|---|---|
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Natriuretic Peptide, Brain; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Prognosis; Recurrence; Rituximab; Survival Analysis; Survival Rate; Treatment Outcome; Troponin T | 2006 |
Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Doxorubicin; Drug Administration Schedule; Humans; Irinotecan; Leukopenia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Recurrence | 2000 |
6 other study(ies) available for irinotecan and Lymphoma, B-Cell
| Article | Year |
|---|---|
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Lymphoma, B-Cell; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2012 |
[Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Remission Induction; Salvage Therapy; Treatment Outcome | 2005 |
Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Salvage Therapy | 1999 |
Hepatic tumor rupture following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fatal Outcome; Humans; Irinotecan; Liver; Liver Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Rupture; Tumor Lysis Syndrome | 1999 |
[Irinotecan (topoisomerase-I inhibitor) for the treatment of recurrent primary intracranial malignant lymphoma].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cerebellar Neoplasms; Cranial Irradiation; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local | 2000 |